LIST OF DRUG CANDIDATES TARGETING NASH(updated weekly)

Click on the name of drug to access data sheet

OCALIVA (OCA), Laboratory : INTERCEPT

Type of drug : FXR Agonist

Clinical trials advancement : Ongoing Procedures to Agreement

The drug got the Breakthrough Therapy Status granted by the FDA and is eligible for Subpart H on intermediate results of Phase 3

Estimated Time to market in months : 5

ELAFIBRANOR (GFT505), Laboratory : GENFIT

Type of drug : dual PPAR alpha delta agonist

Clinical trials advancement : Ongoing Phase 3

The drug got the Fast Track Status granted by the FDA and is eligible for Subpart H on intermediate results of Phase 3

Estimated Time to market in months : 15

CENICRIVIROC (CENICRIVIROC), Laboratory : ALLERGAN

Type of drug : CCR2CCR5 Antagonist

Clinical trials advancement : Ongoing Phase 3

The drug got the Fast Track Status granted by the FDA and is eligible for Subpart H on intermediate results of Phase 3

Estimated Time to market in months : 25

RESMETIROM (MGL_3196), Laboratory : MADRIGAL

Type of drug : THR-β Agonist

Clinical trials advancement : Recruiting Phase 3

and is eligible for Subpart H on intermediate results of Phase 3

Estimated Time to market in months : 38

BELAPECTIN (GR_MD_02), Laboratory : GALECTIN

Type of drug : Galectin Inhibitor

Clinical trials advancement : Initiating Phase 3

The drug got the Fast Track Status granted by the FDA

Estimated Time to market in months : 55

IMM124E (IMM124E), Laboratory : IMMURON

Type of drug : anti-LPS antibodies and adjuvants

Clinical trials advancement : Initiating Phase 3

The drug got the Breakthrough Therapy Status granted by the FDA

Estimated Time to market in months : 55

FIRSOCOSTAT (GS0976), Laboratory : GILEAD

Type of drug : ACC inhibitor

Clinical trials advancement : Initiating Phase 3

The drug got the Fast Track Status granted by the FDA

Estimated Time to market in months : 56

ARAMCHOL (ARAMCHOL), Laboratory : GALMED

Type of drug : FABACs

Clinical trials advancement : Analysing Results Phase 2b

The drug got the Fast Track Status granted by the FDA

Estimated Time to market in months : 55

CILOFEXOR (GS9674), Laboratory : GILEAD

Type of drug : FXR agonist

Clinical trials advancement : Analysing Results Phase 2b

Estimated Time to market in months : 80

MSDC_0602 (MSDC_0602), Laboratory : CIRIUS_THERAPEUTICS

Type of drug : mTOT modulating insulin sensitizer

Clinical trials advancement : Analysing Results Phase 2b

Estimated Time to market in months : 88

TROPIFEXOR (LJN452), Laboratory : NOVARTIS

Type of drug : non-BA FXR agonist

Clinical trials advancement : Ongoing Phase 2b

Estimated Time to market in months : 92

SEMAGLUTIDE (SEMAGLUTIDE), Laboratory : NOVONORDISK

Type of drug : GLP_1analog

Clinical trials advancement : Ongoing Phase 2b

Estimated Time to market in months : 92

LANIFIBRANOR (IVA337), Laboratory : INVENTIVA

Type of drug : tri PPAR α δ γ

Clinical trials advancement : Ongoing Phase 2b

The drug got the Fast Track Status granted by the FDA

Estimated Time to market in months : 69

NGM282 (NGM282), Laboratory : NGMBioPHARM

Type of drug : FGF19 hormon

Clinical trials advancement : Ongoing Phase 2b

Estimated Time to market in months : 94

SELADELPAR (MBX_8025), Laboratory : CYMABAY_THERAPEUTICS

Type of drug : PPAR delta receptor agonist

Clinical trials advancement : Ongoing Phase 2b

Estimated Time to market in months : 100

SAROGLITAZAR (SAROGLITAZAR), Laboratory : ZYDUS

Type of drug : dual PPAR-α γ agonist

Clinical trials advancement : Ongoing Phase 2b

Estimated Time to market in months : 92

LMB763 (LMB763), Laboratory : NOVARTIS

Type of drug : non-BA FXR agonist

Clinical trials advancement : Recruiting Phase 2b

Estimated Time to market in months : 96

PLX_065 (DRX_065), Laboratory : POXEL

Type of drug : stabilized, preferred enantiomer of pioglitazone

Clinical trials advancement : Initiating Phase 2b

Estimated Time to market in months : 82

PF_06835919 (PF_06835919), Laboratory : PFIZER

Type of drug : Ketohexokinase (KHK) Inhibitor

Clinical trials advancement : Initiating Phase 2b

Estimated Time to market in months : 114

BMS986036 (BMS986036), Laboratory : Bristol-MyersSquibb

Type of drug : PEG-FGF21

Clinical trials advancement : Initiating Phase 2b

Estimated Time to market in months : 106

ISOSABUTATE (ISOSABUTATE), Laboratory : NORTHSEA_THERAPEUTICS

Type of drug : SEFA Structurally Engineered Fatty Acid

Clinical trials advancement : Initiating Phase 2b

Estimated Time to market in months : 114

EYP001 (EYP001), Laboratory : ENYOPHARMA

Type of drug : Non BA FXR agonist

Clinical trials advancement : Initiating Phase 2b

Estimated Time to market in months : 114

EDP_305 (EDP_305), Laboratory : ENANTA

Type of drug : FXR agonist

Clinical trials advancement : Analysing Results Phase 2a

The drug got the Fast Track Status granted by the FDA

Estimated Time to market in months : 90

GRI_0621 (GRI_0621), Laboratory : GRIPharma

Type of drug : NKT I Inhibitor

Clinical trials advancement : Analysing Results Phase 2a

Estimated Time to market in months : 114

BMS_986171 (pegbelfermin), Laboratory : Bristol-MyersSquibb

Type of drug : PEG-FGF21

Clinical trials advancement : Analysing Results Phase 2a

Estimated Time to market in months : 114

VK2809 (VK2809), Laboratory : VIKING

Type of drug : THR-? Agonist prodrug

Clinical trials advancement : Analysing Results Phase 2a

Estimated Time to market in months : 96

PF_05221304 (PF_05221304), Laboratory : PFIZER

Type of drug : Acetyl CoA-Carboxylase (ACC) Inhibitor

Clinical trials advancement : Analysing Results Phase 2a

The drug got the Fast Track Status granted by the FDA

Estimated Time to market in months : 92

TIPELUKAST (TIPELUKAST), Laboratory : MEDICINOVA

Type of drug : (5-LOLT) inibitor

Clinical trials advancement : Analysing Results Phase 2a

The drug got the Fast Track Status granted by the FDA

Estimated Time to market in months : 92

NALMEFENE (JKB121), Laboratory : TaiwanJPharmaceuticals

Type of drug : Opioid receptor antagonists; Toll-like receptor 4 antagonists

Clinical trials advancement : Ongoing Phase 2a

Estimated Time to market in months : 116

PF_06865571 (PF_06865571), Laboratory : PFIZER

Type of drug : Diacylglycerol O-Acyltransferase 2 (DGAT2) Inhibitor

Clinical trials advancement : Ongoing Phase 2a

Estimated Time to market in months : 116

LIK066 (LIK066), Laboratory : NOVARTIS

Type of drug : SGLT1-SGLT2 inhibitor

Clinical trials advancement : Ongoing Phase 2a

Estimated Time to market in months : 116

TESAMORELIN (EGRIFTA), Laboratory : Theratechnologies

Type of drug : growth hormone releasing hormone (GHRH) analogue

Clinical trials advancement : Ongoing Phase 2a

Estimated Time to market in months : 98

DF102 (AF102), Laboratory : AFIMMUNE

Type of drug : Undefined mechanism

Clinical trials advancement : Ongoing Phase 2a

The drug got the Fast Track Status granted by the FDA

Estimated Time to market in months : 93

NAMODENOSON (NAMODENOSON), Laboratory : CANFITE

Type of drug : A3AR Agonist

Clinical trials advancement : Ongoing Phase 2a

Estimated Time to market in months : 118

MT_3995 (MT-3995), Laboratory : MitsubishiTanabePharma

Type of drug : Aldosterone receptor antagonists

Clinical trials advancement : Ongoing Phase 2a

Estimated Time to market in months : 119

NITAZOXANIDE (NITAZOXANIDE), Laboratory : GENFIT

Type of drug : Stellate Cell activation

Clinical trials advancement : Ongoing Phase 2a

Estimated Time to market in months : 97

BI_1467335 (BI_1467335 or PXS-4728A), Laboratory : Boehringer_Ingelheim

Type of drug : VAP-1/AOC3 protein inhibitor

Clinical trials advancement : Ongoing Phase 2a

The drug got the Fast Track Status granted by the FDA

Estimated Time to market in months : 96

HTD1801 (HTD1801), Laboratory : HighTideTherapeutics

Type of drug : unknown mechanism of action

Clinical trials advancement : Recruiting Phase 2a

The drug got the Fast Track Status granted by the FDA

Estimated Time to market in months : 98

GEMCABENE (GEMCABENE), Laboratory : GEMPHIRE

Type of drug : enhance the clearance of VLDLs and may also inhibit ACC

Clinical trials advancement : Recruiting Phase 2a

Estimated Time to market in months : 123

FORALUMAB (FORALUMAB), Laboratory : TIZIANA

Type of drug : anti-CD3 monoclonal antibody (mAbs)

Clinical trials advancement : Initiating Phase 2a

Estimated Time to market in months : 124

PXL770 (PXL770), Laboratory : POXEL

Type of drug : (AMPK) activator

Clinical trials advancement : Initiating Phase 2a

Estimated Time to market in months : 125

BIO89_100 (TEV_47948), Laboratory : 89BIO

Type of drug : glycopegylated FGF21 analogue

Clinical trials advancement : Initiating Phase 2a

Estimated Time to market in months : 117

SGM_1019 (SGM_1019), Laboratory : SecondGenome

Type of drug : P2X7 inhibitor

Clinical trials advancement : Initiating Phase 2a

Estimated Time to market in months : 124

SAR425899 (SAR425899), Laboratory : SANOFI

Type of drug : GLP-1/GCGR agonist

Clinical trials advancement : Initiating Phase 2a

Estimated Time to market in months : 125

SOTAGLIFLOZIN (LX4211), Laboratory : SANOFI

Type of drug : DUAL SGLT1 SGLT2 Inhibitor

Clinical trials advancement : Initiating Phase 2a

Estimated Time to market in months : 125

ELOBIXIBAT (A4250), Laboratory : AlbireoPharma

Type of drug : ileal bile acid transported (IBAT)

Clinical trials advancement : Initiating Phase 2a

Estimated Time to market in months : 125

TERN_101 (TERN_101), Laboratory : TERNS

Type of drug : FXR Agonist

Clinical trials advancement : Initiating Phase 2a

The drug got the Fast Track Status granted by the FDA

Estimated Time to market in months : 101

CER_209 (CER_209), Laboratory : CERENIS

Type of drug : P2Y13 receptor agonist

Clinical trials advancement : Initiating Phase 2a

Estimated Time to market in months : 125

HEPASTEM (HEPASTEM), Laboratory : PROMETHERA

Type of drug : human liver derived mesenchymal stem

Clinical trials advancement : Initiating Phase 2a

Estimated Time to market in months : 125

BEZAFIBRATE (BEZAFIBRATE), Laboratory : INTERCEPT

Type of drug : tri PPAR alpha delta gamma

Clinical trials advancement : Initiating Phase 2a

Estimated Time to market in months : 131

KBP_042 (KBP_042), Laboratory : NORDICBIOSCIENCE

Type of drug : (DACRA)

Clinical trials advancement : Analysing Results Phase 1

Estimated Time to market in months : 125

DUR928 (DUR_928), Laboratory : DURECT

Type of drug : epigenetically-active endogenous small molecule

Clinical trials advancement : Analysing Results Phase 1

Estimated Time to market in months : 126

NGM313 (MK-3655), Laboratory : Merck/NGMBio

Type of drug : β-Klotho/FGFR1c receptor

Clinical trials advancement : Analysing Results Phase 1

Estimated Time to market in months : 126

LPCN_1144 (LPCN_1144), Laboratory : LIPOCINE

Type of drug : novel oral prodrug of testosterone containing testosterone undecanoate

Clinical trials advancement : Analysing Results Phase 1

Estimated Time to market in months : 129

NAMACIZUMAB (RYI-018 or JNJ-2463), Laboratory : BIRDROCKBIO

Type of drug : NAMA-CB1

Clinical trials advancement : Analysing Results Phase 1

Estimated Time to market in months : 129

ND_L02_s0201 (ND_L02_s0201), Laboratory : NITTODENKO

Type of drug : (SERPINH1) (Hsp47)

Clinical trials advancement : Ongoing Phase 1

Estimated Time to market in months : 130

RTU_1096 (RTU_1096), Laboratory : SUCAMPO

Type of drug : Vap-1 inhibitor

Clinical trials advancement : Ongoing Phase 1

Estimated Time to market in months : 130

IONIS_DGAT2Rx (IONIS_DGAT2Rx), Laboratory : IONISPHARMA

Type of drug : DGAT2Rx

Clinical trials advancement : Ongoing Phase 1

Estimated Time to market in months : 131

INT_767 (INT_767), Laboratory : INTERCEPT

Type of drug : farnesoid X receptor (FXR) and TGR5, a G-protein coupled bile acid receptor

Clinical trials advancement : Ongoing Phase 1

Estimated Time to market in months : 133

CM_101 (CM_101), Laboratory : ChemomAb

Type of drug : anti CCL24 monoclonal antibody

Clinical trials advancement : Recruiting Phase 1

Estimated Time to market in months : 136

TERN_201 (TERN_201), Laboratory : TERNS

Type of drug : SSAO Inhibitor

Clinical trials advancement : Recruiting Phase 1

Estimated Time to market in months : 136

HM15211 (HM15211), Laboratory : HanmiPharmaceutical

Type of drug : long-acting GLP-1, GIP and glucagon triple agonist

Clinical trials advancement : Recruiting Phase 1

Estimated Time to market in months : 136

NC_001 (NC_001), Laboratory : NAIAPHARMA

Type of drug : act on insulin resistance

Clinical trials advancement : Recruiting Phase 1

Estimated Time to market in months : 136